Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jazz And Concert In Tune On Xyrem

This article was originally published in The Pink Sheet Daily

Executive Summary

The two biotech companies have teamed up to create a follow-on product to Jazz’s narcolepsy drug, a collaboration that could add to the patent-life of Xyrem and be financially beneficial for both companies.

You may also be interested in...



Not Jazzed About Xyrem REMS, Irish Company Begins Dispute Resolution

Jazz will begin dispute resolution with FDA regarding the risk evaluation and mitigation strategy for its best-selling wakefulness drug.

In Wake Of Deals, Concert Is Latest To File For IPO

Lexington, Mass.-based Concert became the second company studying deuterium chemistry in the current pipeline for initial public offerings. It joins Auspex, which updated its filing this week, as did pain drug developer Cara.

Concert Secures Celgene As Its Latest Partner

Concert Pharmaceuticals has garnered a third partnership for its deuterium-modification platform as the Massachusetts biotech continues to push its internal pipeline forward on its own.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS075328

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel